| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sofie A M K Houthoofd, Manuel Morrens, Bernard G C Sabb. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clinical therapeutics. vol 30. issue 9. 2009-01-06. PMID:18840365. |
the aim of this review was to discuss data from double-blind, randomized controlled trials (rcts) that have investigated the effects of oral and long-acting injectable risperidone on cognitive and psychomotor functioning in patients with schizophrenia or schizoaffective disorder. |
2009-01-06 |
2023-08-12 |
Not clear |
| S M Tamrakar, M K Nepal, N R Koirala, V D Sharma, C K Gurung, S R Adhikar. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia. Kathmandu University medical journal (KUMJ). vol 4. issue 2. 2008-12-15. PMID:18603890. |
an open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia. |
2008-12-15 |
2023-08-12 |
Not clear |
| Shelly Tadger, Yehuda Baruch, Yoram Bara. Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone. International psychogeriatrics. vol 20. issue 6. 2008-12-12. PMID:18620626. |
symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone. |
2008-12-12 |
2023-08-12 |
Not clear |
| Hans-Jürgen Möller, Michael Riedel, Markus Jäger, Florian Wickelmaier, Wolfgang Maier, Kai-Uwe Kühn, Gerhard Buchkremer, Isabella Heuser, Joachim Klosterkötter, Markus Gastpar, Dieter F Braus, Ralf Schlösser, Frank Schneider, Christian Ohmann, Mathias Riesbeck, Wolfgang Gaebe. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. The international journal of neuropsychopharmacology. vol 11. issue 7. 2008-12-08. PMID:18466670. |
short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the german research network on schizophrenia. |
2008-12-08 |
2023-08-12 |
Not clear |
| Hans-Jürgen Möller, Michael Riedel, Markus Jäger, Florian Wickelmaier, Wolfgang Maier, Kai-Uwe Kühn, Gerhard Buchkremer, Isabella Heuser, Joachim Klosterkötter, Markus Gastpar, Dieter F Braus, Ralf Schlösser, Frank Schneider, Christian Ohmann, Mathias Riesbeck, Wolfgang Gaebe. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. The international journal of neuropsychopharmacology. vol 11. issue 7. 2008-12-08. PMID:18466670. |
risperidone and haloperidol appear to be equally effective in treating negative and other symptoms of first-episode schizophrenia. |
2008-12-08 |
2023-08-12 |
Not clear |
| Dan Cooper, Jocelyne Moisan, Belkacem Abdous, Jean-Pierre Grégoir. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. vol 15. issue 3. 2008-12-05. PMID:18953083. |
a population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia. |
2008-12-05 |
2023-08-12 |
Not clear |
| Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Shinichiro Nakajima, Kensuke Nomura, Hiroyoshi Takeuchi, Akira Tanabe, Gohei Yagi, Haruo Kashim. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Human psychopharmacology. vol 23. issue 6. 2008-11-18. PMID:18537222. |
effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. |
2008-11-18 |
2023-08-12 |
Not clear |
| K Jack Ishak, Ye Tan, Jennifer Glass, Doanh Luong, J Jaime Car. Risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia. Clinical therapeutics. vol 30. issue 7. 2008-11-18. PMID:18691984. |
risk of discontinuation of risperidone after exposure to potentially interacting drugs: a nested case-control study in patients with schizophrenia. |
2008-11-18 |
2023-08-12 |
Not clear |
| Linmarie Sikich, Jean A Frazier, Jon McClellan, Robert L Findling, Benedetto Vitiello, Louise Ritz, Denisse Ambler, Madeline Puglia, Ann E Maloney, Emily Michael, Sandra De Jong, Karen Slifka, Nancy Noyes, Stefanie Hlastala, Leslie Pierson, Nora K McNamara, Denise Delporto-Bedoya, Robert Anderson, Robert M Hamer, Jeffrey A Lieberma. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. The American journal of psychiatry. vol 165. issue 11. 2008-11-18. PMID:18794207. |
this study compared the efficacy and safety of two second-generation antipsychotics (olanzapine and risperidone) with a first-generation antipsychotic (molindone) in the treatment of early-onset schizophrenia and schizoaffective disorder. |
2008-11-18 |
2023-08-12 |
Not clear |
| Bo Gu, Lei Wang, Ai-Ping Zhang, Gang Ma, Xin-Zhi Zhao, Hua-Fang Li, Guo-Ying Feng, Lin He, Qing-He Xin. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenetics and genomics. vol 18. issue 8. 2008-11-12. PMID:18622264. |
association between a polymorphism of the htr3a gene and therapeutic response to risperidone treatment in drug-naive chinese schizophrenia patients. |
2008-11-12 |
2023-08-12 |
Not clear |
| Bo Gu, Lei Wang, Ai-Ping Zhang, Gang Ma, Xin-Zhi Zhao, Hua-Fang Li, Guo-Ying Feng, Lin He, Qing-He Xin. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenetics and genomics. vol 18. issue 8. 2008-11-12. PMID:18622264. |
few studies have, however, focused on the association between the therapeutic responses to atypical antipsychotics, such as risperidone, and polymorphisms of the 5-ht3 receptor, the only ionotropic ligand-gated serotonin receptor, even though there have been some genetic clues linking htr3a and schizophrenia. |
2008-11-12 |
2023-08-12 |
Not clear |
| b' Branka Aukst-Margeti\\xc4\\x87, Branimir Margeti\\xc4\\x8. Treatment of generalized tardive dystonia with clozapine. Psychiatria Danubina. vol 20. issue 3. 2008-11-12. PMID:18827758.' |
we report a case of a 35-year-old patient with schizophrenia who developed a generalized form of tardive dystonia after switching of clozapine to risperidone treatment that persisted after switch to olanzapine and during the period while treatment with an antipsychotic was discontinued. |
2008-11-12 |
2023-08-12 |
Not clear |
| Borah Kim, Sang-Hyuk Lee, Tae Kyou Choi, ShinYoung Suh, Yong Woo Kim, EunHee Lee, Ki Hwan Yoo. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 5. 2008-11-05. PMID:18442879. |
effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. |
2008-11-05 |
2023-08-12 |
Not clear |
| Borah Kim, Sang-Hyuk Lee, Tae Kyou Choi, ShinYoung Suh, Yong Woo Kim, EunHee Lee, Ki Hwan Yoo. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 5. 2008-11-05. PMID:18442879. |
we examine whether risperidone long-acting injection (rlai) could effectively act to prevent relapse in first-episode schizophrenia. |
2008-11-05 |
2023-08-12 |
Not clear |
| Borah Kim, Sang-Hyuk Lee, Tae Kyou Choi, ShinYoung Suh, Yong Woo Kim, EunHee Lee, Ki Hwan Yoo. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 5. 2008-11-05. PMID:18442879. |
22 patients with schizophrenia were assigned to the rlai group and 28 patients with schizophrenia to the oral risperidone group as control. |
2008-11-05 |
2023-08-12 |
Not clear |
| V A Curtis, K Katsafouros, H-J Möller, R Medori, E Sacchett. Long-acting risperidone improves negative symptoms in stable psychotic patients. Journal of psychopharmacology (Oxford, England). vol 22. issue 3. 2008-10-23. PMID:18308804. |
the aim of this paper was to evaluate the efficacy of risperidone long-acting injectable (rlai) for reducing negative symptoms of schizophrenia in patients with predominantly negative symptoms at baseline. |
2008-10-23 |
2023-08-12 |
Not clear |
| Carla M Canuso, Eriene A Youssef, Cynthia A Bossie, Ibrahim Turkoz, Andreas Schreiner, George M Simpso. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. International clinical psychopharmacology. vol 23. issue 4. 2008-10-17. PMID:18545059. |
paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. |
2008-10-17 |
2023-08-12 |
Not clear |
| Luca Pani, José M Villagrán, Vassilis P Kontaxakis, Köksal Alpteki. Practical issues with amisulpride in the management of patients with schizophrenia. Clinical drug investigation. vol 28. issue 8. 2008-10-17. PMID:18598092. |
amisulpride is an atypical antipsychotic with a significantly greater effect size than first-generation, typical antipsychotics, and efficacy at least similar to that of olanzapine and risperidone in large-scale clinical trials in schizophrenia. |
2008-10-17 |
2023-08-12 |
Not clear |
| Hiroyuki Uchida, David C Mamo, Shitij Kapur, Alain Labelle, Chekkera Shammi, Erik J L Mannaert, Steve W Mann, Gary Remingto. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. The Journal of clinical psychiatry. vol 69. issue 8. 2008-10-15. PMID:18642974. |
monthly administration of long-acting injectable risperidone and striatal dopamine d2 receptor occupancy for the management of schizophrenia. |
2008-10-15 |
2023-08-12 |
Not clear |
| Hiroyuki Uchida, David C Mamo, Shitij Kapur, Alain Labelle, Chekkera Shammi, Erik J L Mannaert, Steve W Mann, Gary Remingto. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. The Journal of clinical psychiatry. vol 69. issue 8. 2008-10-15. PMID:18642974. |
long-acting risperidone administered intramuscularly biweekly is approved for the management of schizophrenia. |
2008-10-15 |
2023-08-12 |
Not clear |